Network Insights Methodology Get Access

Eli Lilly

PERSON Health Care / Pharmaceutical Products & Services Momentum 8.1ML Momentum Score (0-100). Weighted composite of 9 features: mention velocity, article breadth, relationship density, deal context, recency, market cap, enrichment completeness, mention concentration, entity type. NORMALPSI regime classification. QUIET (<0.3): baseline activity. NORMAL (0.3-0.5): typical deal flow. ELEVATED (0.5-0.7): above-average signals. HIGH (0.7-0.85): significant activity. EXTREME (>0.85): exceptional signal concentration. Primary: Spectral Shift

$48.3B revenue (2025), Indianapolis-based Eli Lilly manufactures insulin, GLP-1 diabetes treatments, and oncology drugs. Stock surged 40% in 2025 on Mounjaro/Zepbound blockbuster demand and expanded GCC/LATAM market penetration.

Active M&A and licensing activity in GCC and LATAM regions; healthcare portfolio expansion across oncology, immunology, and diabetes therapeutics
-0.71
PSI ScorePlocamium Signal Index - composite z-score from 5 orthogonal signals: news frequency, targeted sentiment, graph centrality, regulatory filings, and clinical trial activity.
8.1
MomentumML Momentum Score (0-100). Weighted composite of 9 features including mention velocity, article breadth, deal context, and relationship density. Retrained weekly.
1%
ConfidenceSignal confidence - percentage of PSI sub-signals with sufficient data (30+ observations). Higher confidence means the PSI score is based on more complete data.
25
ConnectionsDegree centrality - number of unique entities this entity co-occurs with in news signals and articles. Higher = more connected in the intelligence network.
Connected Entities
NYSE Morgan Stanley FDA Novo Nordisk Nvidia United States Apple Bloomberg Alphabet Amazon Elon Musk Microsoft SEC SpaceX Tesla
Watch This Entity
PSI Intelligence
30-Day Trend
2026-04-25 2026-05-25 26 0 Degree Mentions
Signal Decomposition
Attention Cascade
3.333
Narrative Drift
0.310
Spectral Shift
624.046
Sentiment-Momentum Divergence
0.000
Source Concentration
0.253
Peer Comparison
Not yet ranked. Sector-relative scoring requires at least four entities in the same BICS sector with PSI history; this entity does not yet meet the threshold or sits in a sector with insufficient peers.
Network Analysis
25 Degree Centrality
Ego Network (top connections)
NYSE (weight 22.0)Morgan Stanley (weight 18.0)FDA (weight 8.0)Novo Nordisk (weight 8.0)Nvidia (weight 5.0)United States (weight 5.0)Apple (weight 4.0)Bloomberg (weight 4.0) NYSEMorgan StanleyFDANovo NordiskNvidiaUnited StatesAppleBloomberg Eli Lilly (degree 25) Eli Lilly
Centrality History
2026-04-25 2026-05-25 26 0 Degree Mentions
EntityWeight StatusFirst Seen
NYSE 22 NEW
Morgan Stanley 18 NEW
FDA 8 NEW
Novo Nordisk 8 NEW
Nvidia 5 NEW
United States 5 NEW
Apple 4 NEW
Bloomberg 4 NEW
Alphabet 3 NEW
Amazon 3 NEW
Elon Musk 3 NEW
Microsoft 3 NEW
SEC 3 NEW
SpaceX 3 NEW
Tesla 3 NEW
Walmart 3 NEW
AstraZeneca 3 NEW
China 2 NEW
Hong Kong 2 NEW
Intel 2 NEW
Merck 2 NEW
CEO 2 NEW
M&A 2 NEW
Donald Trump 2 NEW
Jim Cramer 2 NEW
Article Coverage (0)
DateLaneTitle
No Plocamium-authored coverage yet. This entity surfaces in upstream signals (news, filings, trials) but has not yet been a primary subject of a published article. Watch this entity to be alerted when one is published.

Request Access

Full PSI intelligence, network analysis, EDGAR filings, and predicted links require an access token.

Data as of 2026-05-25 ← Intelligence Network